STOCK TITAN
  1. Home
  2. News
  3. ZTS

ZOETIS INC. - ZTS STOCK NEWS

Welcome to our dedicated page for ZOETIS news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on ZOETIS stock.

Zoetis Inc. (symbol: ZTS) is a leading American pharmaceutical company and the world's largest producer of medicines and vaccinations for pets and livestock. Originally a subsidiary of Pfizer, Zoetis became an independent company following Pfizer’s spinoff of its 83% interest. Zoetis specializes in a wide range of products including anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals.

The company's revenue is split between production animals (cattle, pigs, poultry, etc.), which contribute approximately 35%, and companion animals (dogs, horses, cats), which account for nearly 65%. In the U.S., Zoetis' business is predominantly focused on companion animals, while its international operations have a slight inclination towards production animals. As an industry leader, Zoetis holds the largest market share and continues to lead in innovation and product development for animal health.

Recent achievements include the launch of new vaccines and diagnostic tools aimed at improving animal health and productivity. Financially, Zoetis remains robust with consistent revenue growth and strategic partnerships to expand its market reach. Current projects include advancing their R&D pipeline to develop next-generation animal health solutions and expanding their global footprint through acquisitions and collaborations.

Stay updated with the latest performance metrics, developments, and events related to Zoetis Inc. to make informed investment decisions.

News

Zoetis Appoints Gavin D.K. Hattersley to its Board of Directors

Rhea-AI Summary
Zoetis Inc. (NYSE: ZTS) appoints Gavin D.K. Hattersley, President and CEO of Molson Coors Beverage Company, to its Board of Directors. Hattersley brings global public company leadership and board experience, enhancing Zoetis' expansion in key markets. His appointment reflects Zoetis' commitment to innovation and customer-centric animal health solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
management
-
News

Zoetis to Host Webcast and Conference Call on First Quarter 2024 Financial Results

Rhea-AI Summary
Zoetis Inc. (ZTS) will host a webcast and conference call to review first quarter 2024 financial results with CEO Kristin Peck and CFO Wetteny Joseph. Investors can access the live webcast on May 2, 2024, with a replay available later.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
conferences earnings
-
News

Zoetis to Participate in the Barclays Global Healthcare Conference

Rhea-AI Summary
Zoetis Inc. (ZTS) to participate in the Barclays Global Healthcare Conference on March 14, 2024. Wetteny Joseph, CFO, to represent the company. Live webcast and replay available for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
conferences
News

Zoetis to Participate in the Bank of America Securities 2024 Animal Health Summit

Rhea-AI Summary
Zoetis Inc. (ZTS) will participate in the Bank of America Securities 2024 Animal Health Summit with Wetteny Joseph, the CFO, presenting on February 29, 2024. The event will be live-streamed for investors and analysts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
conferences
-
News

Zoetis Reports Fourth Quarter and Full Year 2023 Results

Rhea-AI Summary
Zoetis Inc. (NYSE: ZTS) reports revenue of $2.2 billion for Q4 2023, growing 8%, with net income of $525 million, increasing 14%. Full-year 2023 revenue is $8.5 billion, growing 6%, with net income of $2.3 billion, increasing 11%. Full-year 2024 revenue guidance is $9.075 - $9.225 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.71%
Tags
earnings
-
News

Zoetis Declares Second Quarter 2024 Dividend

Rhea-AI Summary
Zoetis Inc. (ZTS) has declared a dividend of $0.432 per share for the second quarter of 2024, payable on June 4, 2024, to all holders of record of the Company’s common stock as of April 19, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
dividends earnings
News

Zoetis Wins 2024 Catalyst Award

Rhea-AI Summary
Zoetis Inc. (ZTS) has been awarded the 2024 Catalyst Award for its global initiative 'Awareness and Action Drives Impact' aimed at advancing Diversity, Equity, and Inclusion (DE&I). As the first animal health company to receive this honor, Zoetis has demonstrated a commitment to fostering a diverse, inclusive environment. The company's efforts have resulted in significant increases in women's representation at various levels within the organization, including the Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
-
News

2024 Feather in Her Cap and High Flyer Award Winners Named for Outstanding Achievements in Animal Health Industry

Rhea-AI Summary
The 2024 Feather in Her Cap awards ceremony honored 11 women for their outstanding career achievements in Animal Health, including Andrea J. Gonzales, Ph.D., of Zoetis, Inc. (NYSE: ZTS), and Katharina Bohnenblust, Ph.D., of Elanco Animal Health (NYSE: ELAN). Dr. Gonzales, Vice President of Global Companion Animal Therapeutics at Zoetis, was recognized for her leadership and contributions to the industry, while Dr. Bohnenblust received the 2024 High Flyer award for her accomplishments in pharmaceutical development. The awards aim to inspire the next generation of industry leaders and recognize women's achievements in Animal Health. Dr. Gonzales' passion for building an innovative R&D pipeline of animal health therapeutics and her commitment to mentoring women in the industry were highlighted, and she chose Cheff Therapeutic Riding Center in Kalamazoo, Michigan, as the recipient of a $5,000 charitable donation. Dr. Bohnenblust, who serves as a mentor for young female scientists, developed the new Elanco JAK-inhibitor formulation and manufacturing process. The Feather in Her Cap Association will reopen the nomination process in Q3 of 2024 to celebrate more outstanding women in Animal Health in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
none
-
News

Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary
Zoetis Inc. (NYSE:ZTS) to host webcast and conference call to review Q4 and full year 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
conferences earnings
News

Zoetis to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Zoetis Inc. (NYSE:ZTS) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. Investors and other interested parties can access a live audio webcast of the presentation on http://investor.zoetis.com/events-presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
conferences

FAQ

What is the current stock price of ZOETIS (ZTS)?

The current stock price of ZOETIS (ZTS) is $176.42 as of November 18, 2024.

What is the market cap of ZOETIS (ZTS)?

The market cap of ZOETIS (ZTS) is approximately 79.5B.

What does Zoetis Inc. specialize in?

Zoetis Inc. specializes in medicines and vaccinations for pets and livestock, including anti-infectives, vaccines, parasiticides, diagnostics, and other health products.

Is Zoetis Inc. still part of Pfizer?

No, Zoetis Inc. became an independent company after Pfizer spun off its 83% interest.

What percentage of Zoetis' revenue comes from companion animals?

Nearly 65% of Zoetis' revenue comes from companion animal products such as those for dogs, horses, and cats.

Which segment contributes more to Zoetis' U.S. business?

Zoetis' U.S. business is heavily skewed toward companion animals.

How does Zoetis' international business differ from its U.S. business?

Internationally, Zoetis' business is slightly skewed towards production animals, unlike its U.S. business, which focuses more on companion animals.

What recent achievements has Zoetis Inc. accomplished?

Recent achievements include the launch of new vaccines and diagnostic tools aimed at improving animal health and productivity.

What are Zoetis' current projects?

Current projects include advancing their R&D pipeline to develop next-generation animal health solutions and expanding their global footprint through acquisitions and collaborations.

What is Zoetis' market position in the industry?

Zoetis holds the largest market share in the animal health industry.

Does Zoetis have any strategic partnerships?

Yes, Zoetis has strategic partnerships to expand its market reach and foster innovation.

Where can I find the latest updates on Zoetis Inc.?

You can stay updated with the latest performance metrics, developments, and events related to Zoetis Inc. on StockTitan and other financial news platforms.

Stock ZTS logo
ZOETIS INC.

NYSE:ZTS

ZTS Rankings

#173 Ranked by Market Cap
#1825 Ranked by Dividends

ZTS Stock Data

79.51B
451.17M
0.2%
96.44%
0.97%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
PARSIPPANY